An observational study in Stroke, Acute and Stroke, Ischemic, sponsored by POLYSAN Scientific & Technological Pharmaceutical Company. Recruiting at 17 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by POLYSAN Scientific & Technological Pharmaceutical Company · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Ischemic Stroke with a site in Russia — 13 open to participants now, 13 under way, 2 of them phase 3. Ischemic Stroke · Russia.
Among the 17 studies in Ischemic Stroke with a site in Russia, this one is one of 4 that started in 2024, is one of 8 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 7th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →13 of the 17 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:
Supergene, LLC · Sites in Russia
Ages 18+
Pharmasoft · Sites in Russia
Ages 18–90 · Healthy volunteers
Tatchempharmpreparaty, JSC · Sites in Russia
Ages 35–80
Pirogov Russian National Research Medical University · Sites in Russia
Ages 40–80
National Society for Neurosonology and Cerebral Circulation · Sites in Russia
Ages 18–85
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 562 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 120 across the 9 interventional studies, 448 across the 8 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 17 have an industry lead sponsor. The 10 most frequent:
POLYSAN Scientific & Technological Pharmaceutical Company is the lead sponsor of 24 studies on the registry; 4 are open to participants now.
POLYSAN Scientific & Technological Pharmaceutical Company has 3 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
6 of the studies in Ischemic Stroke with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07912151Samara State Medical UniversityDynamic Stabilometry Combined With Transcranial Direct Current Stimulation for Balance and Motor Recovery After Ischemic Stroke | 2026-12-28 |
| NCT06175715Pirogov Russian National Research Medical UniversityGeneral Versus Regional Anesthesia for Carotid Endarterectomy at Acute Ischemic Stroke Trial | 2026-12-31 |
| NCT07520630Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports MedicineNeurophysiological Markers for Prediction of Rehabilitation Outcomes After Ischemic Stroke | 2027-03 |
| NCT07575984PharmasoftMexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke | 2027-04 |
| NCT07083986Pirogov Russian National Research Medical UniversityCarotid Endarterectomy Versus Stenting in Patients With Acute Stage of Ischemic Stroke. | 2027-05-21 |
Add all 6 to your calendar (.ics) → With an account.
Among the 17 studies in Ischemic Stroke with a site in Russia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Stroke remains one of the main socially significant problems in the healthcare in the third millennium. The lethality in persons with history of stroke by the end of the 1st year of disease is high. A trend to increased frequency of stroke in the young age is observed during the last decade; third of patients is working-age individuals, out of whom only 15-20% returns to labor, and others remain disabled persons requiring constant medical and social support
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
This study's planned enrollment of 562 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →POLYSAN Scientific & Technological Pharmaceutical Company is the lead sponsor of 24 studies on the registry; 4 are open to participants now.
Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients aged above 18 years with diagnosis of ACVA of ischemic type who did not receive and are not scheduled for reperfusion therapy (thrombolysis, thrombus extraction).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
According to the routine clinical practice, the patient is scheduled to receive the treatment as per one of the following regimens:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Basic therapy + Cytoflavin
Drug: Cytoflavin
Basic therapy (with or without other neuroprotector)
Cytoflavin solution for infusions. 20-40 ml/day (10 ml with the interval of 8-12 hours for 10 days; the single dose is increased up to 20 ml in case of the severe form of the disease) by intravenous drop infusion in dilution per 100-200 ml of 0.9% sodium chloride solution for 10 days; rate of administration: 3-4 ml/min
Percentage of patients with favorable functional outcome (score 0-2) according to Modified Rankin Scale (mRS) on Day of Discharge (assessment at Visit 4 or Visit 5, on Day of Discharge) and on Day 90;
Modified Rankin Scale (mRS)
Time frame: Base, day 14, day 21, day 90
Total score according to Modified Rankin Scale (mRS) on Day of Discharge and Day 90 in the test and control group;
Modified Rankin Scale (mRS)
Time frame: Day 14, day 21, day 90
Total score according to Rivermead Scale on Day 7, Day 14, Day 21, and Day 90 in the test and control group
Rivermead Scale
Time frame: Day 7, day 14, day 21, day 90
Change of the total score according to National Institute of Health Stroke Scale (NIHSS) on Day 3, Day 7, Day 14, and Day 21 as compared to the baseline level (Day 1);
National Institute of Health Stroke Scale (NIHSS)
Time frame: Day 7, day 14, day 21, day 90
Change of the total score according to Stroke-Specific Quality of Life Scale (SS-QOL) on Day 90 as compared to Day of Discharge;
Stroke-Specific Quality of Life Scale (SS-QOL)
Time frame: Day 14, day 21, day 90
Percentage of patients with repeated ACVA or TIA during the study;
Repeated ACVA or TIA
Time frame: Day 90
Percentage of patients with lethal outcome in the period of hospitalization and follow-up
Lethal outcome
Time frame: Day 90
Started Mar 2024 (actual). Primary completion is estimated for Jun 2027, 39 months after the start.
Of 42 industry-sponsored observational studies under Ischemic Stroke, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 39 months is above that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Sep 2025 → Jun 2027 and completion Nov 2025 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
POLYSAN Scientific & Technological Pharmaceutical Company →